Table 2 Characteristics of included studies about OH
Study | Country | Study design | Etiology | Sample (F, %) | Age (T/HCs) | TSH (mIU/l) (T/HCs) a | FT4 (pmol/l) (T/HCs) a | LT4 dosage (µg/d) | Treatment periods | Scale of quality score |
|---|---|---|---|---|---|---|---|---|---|---|
Kung et al., 1991 [27] | China | cross-sectional | Hashimoto’s thyroiditis | 120 (100) | 32.80 ± 6.40/ 32.60 ± 6.70 | 2.20 ± 1.40/ 2.40 ± 0.90 | N/A | 106 ± 37 | 7.5 y | 7 |
Franklyn et al., 1994 [24] | UK | case-control | Hashimoto’s thyroiditis, atrophic thyroiditis, a past history of radioiodine treated thyrotoxicosis | 109 (100) | 56.30/ N/A | 1.24 ± 1.29/ 1.73 ± 0.96 | 21.54 ± 5.27/ 15.03 ± 2.17 | 148.67 | 7.2 y | 8 |
Langdahl et al., 1996 [28] | Denmark | cross-sectional | Primary idiopathic (autoimmune) hypothyroidism | 116 (86.2) | 56 ± 12/ 56 ± 11 | 0.04(0.00-5.20)/ 1.00(0.01–3.50) | 115 ± 25/ 88 ± 11 | 163 (75–300) | 13 y | 7 |
Chai et al., 1999 [19] | China | case-control | Primary hypothyroidism | 66 (100) | 48.80 ± 12.80/ 48.40 ± 10.30 | 3.79 ± 2.36/ N/A | 16.76 ± 4.68/ 18.50 ± 7.25 | 92 ± 13 | 11.5 ± 2.5 m | 9 |
Liu et al., 2011 [29] | China | case-control | Primary hypothyroidism | 30 (100) | 36.07 ± 6.65/ 36.47 ± 5.78 | 2.49 ± 0.95/ 2.38 ± 0.94 | 16.43 ± 2.37/ 24.07 ± 2.44 | N/A | N/A | 5 |
Christy et al., 2014 [25] | India | case-control | Primary hypothyroidism | 56 (100) | 40.25 ± 5.31/ 37.96 ± 6.34 | 3.91 ± 2.88/ 2.42 ± 0.83 | N/A | 100–200 | ≥ 5 y | 8 |
Babu et al., 2015 [18] | India | case-control | Primary hypothyroidism | 50 (100) | 40.40 ± 5.09/ 38.08 ± 6.06 | 3.93 ± 2.99/ 2.40 ± 0.85 | N/A | 125 | ≥ 5 y | 8 |
Obling et al., 2021 [26] | Denmark | case-control | Hashimoto’s thyroiditis | 59 (100) | 47 ± 12/ 47 ± 12 | 2.14(0.58–4.32)/ N/A | 2.14 (0.58–4.32)/ N/A | N/A | 15 (14–23) m | 8 |